Should Chlorambucil still be recommendable as a first line therapy in Sézary Syndrome?

Benjamin Gasser^*
, Christoph Iselin
, Emmanuella Guenova

^*Corresponding author for this work

Department of Translational Immunodermatology

Research output: Contribution to journal › Article › peer-review

Original language	English
Article number	155
Pages (from-to)	61-62
Journal	European Journal of Cancer
Volume	229
Issue number	S 1
DOIs	https://doi.org/10.1016/j.ejca.2025.115964
Publication status	Published - 15 Oct 2025

Fields of science

302 Clinical Medicine

Access to Document

10.1016/j.ejca.2025.115964

Cite this

@article{a9c1544f9f5e46e78f02fa8a2efc98a1,

title = "Should Chlorambucil still be recommendable as a first line therapy in S{\'e}zary Syndrome?",

author = "Benjamin Gasser and Christoph Iselin and Emmanuella Guenova",

year = "2025",

month = oct,

day = "15",

doi = "10.1016/j.ejca.2025.115964",

language = "English",

volume = "229",

pages = "61--62",

journal = "European Journal of Cancer",

issn = "1879-0852",

publisher = "Elsevier",

number = "S 1",

}

TY - JOUR

T1 - Should Chlorambucil still be recommendable as a first line therapy in Sézary Syndrome?

AU - Gasser, Benjamin

AU - Iselin, Christoph

AU - Guenova, Emmanuella

PY - 2025/10/15

Y1 - 2025/10/15

U2 - 10.1016/j.ejca.2025.115964

DO - 10.1016/j.ejca.2025.115964

M3 - Article

SN - 1879-0852

VL - 229

SP - 61

EP - 62

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - S 1

M1 - 155

ER -